Algeta ASA (ALGETA.OL)
ALGETA.OL on Oslo Stock Exchange
243.00NOK
10:25am EDT
243.00NOK
10:25am EDT
Price Change (% chg)
kr-1.60 (-0.65%)
kr-1.60 (-0.65%)
Prev Close
kr244.60
kr244.60
Open
kr245.00
kr245.00
Day's High
kr248.00
kr248.00
Day's Low
kr241.30
kr241.30
Volume
36,732
36,732
Avg. Vol
192,581
192,581
52-wk High
kr251.70
kr251.70
52-wk Low
kr139.50
kr139.50
About
Algeta ASA is a Norway-based biotechnology company engaged in the development of targeted cancer therapies based on its alpha-pharmaceutical platform. The Company’s principal product is Alpharadin for the treatment of bone metastases resulting from castration-resistant prostate cancer. The Company’s pipeline also includes... (more)
Overall
| Beta: | 1.39 |
| Market Cap (Mil.): | kr10,706.55 |
| Shares Outstanding (Mil.): | 43.77 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| ALGETA.OL | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 68.55 | 44.65 | 37.87 |
| EPS (TTM): | 3.57 | -- | -- |
| ROI: | 26.93 | -2.30 | 18.70 |
| ROE: | 27.59 | -2.12 | 19.53 |
Bayer, Algeta win FDA approval for prostate cancer drug
FRANKFURT, May 15 - German drugmaker Bayer and its development partner Algeta won approval from U.S. regulators for a prostate cancer drug that could eventually generate more than 1 billion euros ($1.31 billion) in annual sales.
Earnings vs.
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: Wright Reports
|
$460.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

